Labetalol

Practical Diabetes International

Volumn 28, Issue 3, 2011, Pages 139-140

  Kernaghan, D ^a   McKay, G ^b  

^a UK   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LABETALOL; METHYLDOPA; PLACEBO; PROPRANOLOL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN PERFUSION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; KIDNEY PERFUSION; MATERNAL HYPERTENSION; NEUROLOGIC DISEASE; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 79954514338     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1579     Document Type: Article

References (5)

1. Confidential Enquiry into Maternal and Child Health. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer, 2003-2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom; 2007.
2. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. National Institute for Health and Clinical Excellence, 2010.
3. Magee LA, et al,. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens Pregnancya 2009; 28: 312-47.
4. Pasker-de Jong PC, et al,. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG 2010; 117: 1080-6.
5. Chan WS, et al,. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010; 29: 271-83.